HomeCompareGLSEF vs PFE

GLSEF vs PFE: Dividend Comparison 2026

GLSEF yields 51.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLSEF wins by $14717.02M in total portfolio value
10 years
GLSEF
GLSEF
● Live price
51.67%
Share price
$0.12
Annual div
$0.06
5Y div CAGR
43.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14717.07M
Annual income
$13,353,497,340.95
Full GLSEF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GLSEF vs PFE

📍 GLSEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLSEFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLSEF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLSEF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLSEF
Annual income on $10K today (after 15% tax)
$4,391.67/yr
After 10yr DRIP, annual income (after tax)
$11,350,472,739.81/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GLSEF beats the other by $11,350,450,419.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLSEF + PFE for your $10,000?

GLSEF: 50%PFE: 50%
100% PFE50/50100% GLSEF
Portfolio after 10yr
$7358.56M
Annual income
$6,676,761,799.83/yr
Blended yield
90.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GLSEF
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLSEF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLSEFPFE
Forward yield51.67%6.13%
Annual dividend / share$0.06$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR43.6%13.2%
Portfolio after 10y$14717.07M$49.6K
Annual income after 10y$13,353,497,340.95$26,258.71
Total dividends collected$14615.98M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GLSEF vs PFE ($10,000, DRIP)

YearGLSEF PortfolioGLSEF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$18,119$7,419.33$9,153$693.39+$9.0KGLSEF
2$37,429$18,041.71$8,593$849.25+$28.8KGLSEF
3$90,067$50,017.16$8,336$1,066.78+$81.7KGLSEF
4$257,897$161,525.37$8,437$1,384.80+$249.5KGLSEF
5$896,666$620,716.43$9,013$1,875.40+$887.7KGLSEF
6$3,855,768$2,896,335.20$10,306$2,680.72+$3.85MGLSEF
7$20,840,415$16,714,743.36$12,820$4,101.38+$20.83MGLSEF
8$143,544,813$121,245,569.22$17,673$6,826.70+$143.53MGLSEF
9$1,274,366,014$1,120,773,064.53$27,543$12,591.86+$1274.34MGLSEF
10$14,717,068,976$13,353,497,340.95$49,560$26,258.71+$14717.02MGLSEF

GLSEF vs PFE: Complete Analysis 2026

GLSEFStock

Glorious Sun Enterprises Limited, an investment holding company, engages in interior decoration and renovation business in Mainland China, Hong Kong, Australia, New Zealand, Canada, the United States, and internationally. It operates through four segments: Interior Decoration and Renovation; Retail, Franchise and Others; Export Operations; and Financial Investments. The Interior Decoration and Renovation segment engages in the interior decoration and renovation businesses, as well as sale of furniture. The Retail, Franchise and Others segment engages in the retail operation in Hong Kong, as well as franchise sale activities under the Jeanswest brand in casual wear and apparel domain. The Export Operations segment exports apparel. The Financial Investments segment is involved in the treasury management and consulting business. The company also engages in the provision garment design, asset management, and agency services; and property development and management activities. In addition, it offers IT services comprising software products, software customization services, IT infrastructure construction, and IT operation and maintenance services; and logistics services, such as bonded warehouse, warehouse, trade declaration, processing trade, general trade, custom consultancy, shipping agency, loading and unloading, import and export of technology, system software development and technical support, inspection and quarantine, import and export agency, etc. Glorious Sun Enterprises Limited was founded in 1974 and is headquartered in Kowloon Bay, Hong Kong.

Full GLSEF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GLSEF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLSEF vs SCHDGLSEF vs JEPIGLSEF vs OGLSEF vs KOGLSEF vs MAINGLSEF vs JNJGLSEF vs MRKGLSEF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.